Merck Presents Results from P-IIa Clinical Trial of Islatravir (MK-8591) for the Prevention of HIV at IAS 2021
Shots:
- The ongoing P-IIa trial evaluating the safety- tolerability & PK of islatravir (60/120mg- PO- once-monthly for 6 mos.) vs PBO in a ratio (2:2:1) in 242 patients with PrEP of HIV infection for 24 wks.
- The PK analysis showed that the level of islatravir (60/120 mg monthly doses) in PBMCs continues to remain above the pre-specified PK threshold for PrEP & sustained through 8 wks. after a last dose of islatravir. The therapy was generally well tolerated with no serious AEs
- Islatravir is currently being evaluated across a variety of dosing regimens as monothx & in combination with other antiretrovirals for the prevention of HIV including two P-III IMPOWER trials
Ref: Merck | Image: Merck
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com